New study monitors Aimovig's safety in pregnant women with migraine

NCT ID NCT06150781

Recruiting now Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows pregnant women with migraine who take Aimovig (erenumab-aooe) to see if the drug increases the risk of major birth defects. Researchers will compare their babies to those of women with migraine who did not take Aimovig. The goal is to gather real-world safety data for this medication during pregnancy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: erenumab-aooe (Aimovig)
What this could lead to: If successful, this study could provide important safety information about using Aimovig during pregnancy, helping doctors and patients make informed decisions.
What could go wrong: This is an observational registry, not a controlled trial, so it can only show associations, not cause and effect. Results may take years to gather and analyze.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

IQVIA Virtual Site
RECRUITING

Durham, North Carolina, 27703, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.